Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

NAUTIKA1: A Multicenter, Phase II, Neoadjuvant and Adjuvant Study of Multiple Therapies in Biomarker-selected Patients With Resectable Stages IB-III Non-small Cell Lung Cancer

NCT04302025 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT04302025
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04302025 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
NAUTIKA1: A Multicenter, Phase II, Neoadjuvant and Adjuvant Study of Multiple Therapies in Biomarker-selected Patients With Resectable Stages IB-III Non-small Cell Lung Cancer
Lead sponsor
Genentech, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
November 6, 2020
Completion date
May 30, 2030
Enrollment
99 (estimated)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer